Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tafasitamab by Incyte for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Tafasitamab is under clinical development by Incyte and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to GlobalData,...
Opzelura by Incyte for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE): Likelihood of Approval
Opzelura is under clinical development by Incyte and currently in Phase II for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid...
Opzelura by Incyte for Graft Versus Host Disease (GVHD): Likelihood of Approval
Opzelura is under clinical development by Incyte and currently in Phase II for Graft Versus Host Disease (GVHD). According to...
Tafasitamab by Incyte for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Tafasitamab is under clinical development by Incyte and currently in Phase III for Marginal Zone B-cell Lymphoma. According to GlobalData,...
Tafasitamab by Incyte for Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: Likelihood of Approval
Tafasitamab is under clinical development by Incyte and currently in Phase II for Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. According to GlobalData,...
Tafasitamab by Incyte for Non-Hodgkin Lymphoma: Likelihood of Approval
Tafasitamab is under clinical development by Incyte and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase II...
Itacitinib adipate by Incyte for Graft Versus Host Disease (GVHD): Likelihood of Approval
Itacitinib adipate is under clinical development by Incyte and currently in Phase III for Graft Versus Host Disease (GVHD). According...
INCB-161734 by Incyte for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
INCB-161734 is under clinical development by Incyte and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
INCB-161734 by Incyte for Solid Tumor: Likelihood of Approval
INCB-161734 is under clinical development by Incyte and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
INCB-161734 by Incyte for Colorectal Cancer: Likelihood of Approval
INCB-161734 is under clinical development by Incyte and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...
INCB-57643 by Incyte for Myelofibrosis: Likelihood of Approval
INCB-57643 is under clinical development by Incyte and currently in Phase I for Myelofibrosis. According to GlobalData, Phase I drugs...
Itacitinib adipate by Incyte for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
Itacitinib adipate is under clinical development by Incyte and currently in Phase II for Chronic Myelomonocytic Leukemia (CMML). According to...
Povorcitinib phosphate by Incyte for Prurigo: Likelihood of Approval
Povorcitinib phosphate is under clinical development by Incyte and currently in Phase III for Prurigo. According to GlobalData, Phase III...
INCB-099280 by Incyte for Colorectal Cancer: Likelihood of Approval
INCB-099280 is under clinical development by Incyte and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...
Povorcitinib phosphate by Incyte for Vitiligo: Likelihood of Approval
Povorcitinib phosphate is under clinical development by Incyte and currently in Phase III for Vitiligo. According to GlobalData, Phase III...
Retifanlimab by Incyte for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Retifanlimab is under clinical development by Incyte and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According...
Povorcitinib phosphate by Incyte for Vitiligo: Likelihood of Approval
Povorcitinib phosphate is under clinical development by Incyte and currently in Phase III for Vitiligo. According to GlobalData, Phase III...
Pemigatinib by Incyte for Non-Small Cell Lung Cancer: Likelihood of Approval
Pemigatinib is under clinical development by Incyte and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Tuparstobart by Incyte for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Tuparstobart is under clinical development by Incyte and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According...
Risk adjusted net present value: What is the current valuation of Incyte's Povorcitinib?
Povorcitinib is a small molecule commercialized by Incyte, with a leading Phase III program in Hidradenitis Suppurativa. According to Globaldata,...